Kyron.bio utilizes a novel glycan engineering strategy to precisely control glycosylation patterns on biologics, enhancing their safety and efficacy. This technology addresses the unmet therapeutic needs of patients by enabling the development of superior protein therapeutics.
Funding
$590K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for producing protein therapeutics often result in inconsistent glycosylation patterns, which can negatively impact the safety and efficacy of these drugs. Inconsistent glycosylation can lead to reduced therapeutic effect, increased immunogenicity, and suboptimal drug performance.
Solution
Kyron.bio is developing a glycan engineering platform to precisely control glycosylation patterns on biologic drugs, leading to enhanced safety and efficacy. Their technology enables the creation of next-generation antibody therapeutics with improved and consistent glycosylation. By controlling glycosylation, Kyron.bio aims to unlock superior protein therapeutics that can deliver better therapies and transform patient outcomes. The company's novel engineering strategy opens a new era of antibody therapeutics by addressing the limitations of current manufacturing processes.
Target Audience
Kyron.bio's primary customers are pharmaceutical companies and research institutions involved in the development and manufacturing of protein therapeutics, particularly antibody-based drugs.
Features
- Glycan engineering platform for precise control of glycosylation patterns
- Ability to tailor glycosylation to enhance therapeutic effect
- Technology to reduce immunogenicity of biologic drugs
- Improved consistency in glycosylation compared to traditional methods